30 research outputs found
Coactosin-like 1 integrates signaling critical for shear-dependent thrombus formation in mouse platelets
Get PDFPlatelet aggregate formation is a multistep process involving receptor-mediated, as well as biomechanical, signaling cascades, which are highly dependent on actin dynamics. We have previously shown that actin depolymerizing factor (ADF)/n-cofilin and Twinfilin 2a, members of the ADF homology (ADF-H) protein family, have distinct roles in platelet formation and function. Coactosin-like 1 (Cotl1) is another ADF-H protein that binds actin and was also shown to enhance biosynthesis of pro-inflammatory leukotrienes (LT) in granulocytes. Here, we generated mice lacking Cotl1 in the megakaryocyte lineage (Cotl1â/â) to investigate its role in platelet production and function. Absence of Cotl1 had no impact on platelet counts, platelet activation or cytoskeletal reorganization under static conditions in vitro. In contrast, Cotl1 deficiency markedly affected platelet aggregate formation on collagen and adhesion to immobilized von Willebrand factor at high shear rates in vitro, pointing to an impaired function of the platelet mechanoreceptor glycoprotein (GP) Ib. Furthermore, Cotl1â/âplatelets exhibited increased deformability at high shear rates, indicating that the GPIb defect may be linked to altered biomechanical properties of the deficient cells. In addition, we found that Cotl1 deficiency markedly affected platelet LT biosynthesis. Strikingly, exogenous LT addition restored defective aggregate formation of Cotl1â/â platelets at high shear in vitro, indicating a critical role of platelet-derived LT in thrombus formation. In vivo, Cotl1 deficiency translated into prolonged tail bleeding times and protection from occlusive arterial thrombus formation. Together, our results show that Cotl1 in platelets is an integrator of biomechanical and LT signaling in hemostasis and thrombosis
TRPM7 Kinase Controls Calcium Responses in Arterial Thrombosis and Stroke in Mice
Get PDFObjective: TRPM7 (transient receptor potential cation channel, subfamily M, member 7) is a ubiquitously expressed bifunctional protein comprising a transient receptor potential channel segment linked to a cytosolic alpha-type serine/threonine protein kinase domain. TRPM7 forms a constitutively active Mg2+ and Ca2+ permeable channel, which regulates diverse cellular processes in both healthy and diseased conditions, but the physiological role of TRPM7 kinase remains largely unknown. Approach and Results: Here we show that point mutation in TRPM7 kinase domain deleting the kinase activity in mice (Trpm7(R/R)) causes a marked signaling defect in platelets. Trpm7(R/R) platelets showed an impaired PIP2 (phosphatidylinositol-4,5-bisphosphate) metabolism and consequently reduced Ca2+ mobilization in response to stimulation of the major platelet receptors GPVI (glycoprotein VI), CLEC-2 (C-type lectin-like receptor), and PAR (protease-activated receptor). Altered phosphorylation of Syk (spleen tyrosine kinase) and phospholipase C gamma 2 and beta 3 accounted for these global platelet activation defects. In addition, direct activation of STIM1 (stromal interaction molecule 1) with thapsigargin revealed a defective store-operated Ca2+ entry mechanism in the mutant platelets. These defects translated into an impaired platelet aggregate formation under flow and protection of the mice from arterial thrombosis and ischemic stroke in vivo. Conclusions: Our results identify TRPM7 kinase as a key modulator of phospholipase C signaling and store-operated Ca2+ entry in platelets. The protection of Trpm7(R/R) mice from acute ischemic disease without developing intracranial hemorrhage indicates that TRPM7 kinase might be a promising antithrombotic target
Lymphangiogenesis requires Ang2/Tie/PI3K signaling for VEGFR3 cell-surface expression
Get PDFPublisher Copyright: © 2022 American Society for Clinical Investigation. All rights reserved.Vascular endothelial growth factor C (VEGF-C) induces lymphangiogenesis via VEGF receptor 3 (VEGFR3), which is encoded by the most frequently mutated gene in human primary lymphedema. Angiopoietins (Angs) and their Tie receptors regulate lymphatic vessel development, and mutations of the ANGPT2 gene were recently found in human primary lymphedema. However, the mechanistic basis of Ang2 activity in lymphangiogenesis is not fully understood. Here, we used gene deletion, blocking Abs, transgene induction, and gene transfer to study how Ang2, its Tie2 receptor, and Tie1 regulate lymphatic vessels. We discovered that VEGF-C-induced Ang2 secretion from lymphatic endothelial cells (LECs) was involved in full Akt activation downstream of phosphoinositide 3 kinase (PI3K). Neonatal deletion of genes encoding the Tie receptors or Ang2 in LECs, or administration of an Ang2-blocking Ab decreased VEGFR3 presentation on LECs and inhibited lymphangiogenesis. A similar effect was observed in LECs upon deletion of the PI3K catalytic p110α subunit or with smallmolecule inhibition of a constitutively active PI3K located downstream of Ang2. Deletion of Tie receptors or blockade of Ang2 decreased VEGF-C-induced lymphangiogenesis also in adult mice. Our results reveal an important crosstalk between the VEGF-C and Ang signaling pathways and suggest new avenues for therapeutic manipulation of lymphangiogenesis by targeting Ang2/Tie/PI3K signaling.Peer reviewe
The SARS-CoV-2 receptor ACE2 is expressed in mouse pericytes but not endothelial cells : Implications for COVID-19 vascular research
Get PDFHumanized mouse models and mouse-adapted SARS-CoV-2 virus are increasingly used to study COVID-19 pathogenesis, so it is impor-tant to learn where the SARS-CoV-2 receptor ACE2 is expressed. Here we mapped ACE2 expression during mouse postnatal development and in adulthood. Pericytes in the CNS, heart, and pancreas express ACE2 strongly, as do perineurial and adrenal fibroblasts, whereas endothelial cells do not at any location analyzed. In a number of other organs, pericytes do not express ACE2, including in the lung where ACE2 instead is expressed in bronchial epithelium and alveolar type II cells. The onset of ACE2 expression is organ specific: in bronchial epithelium already at birth, in brain pericytes before, andin heart pericytes after postnatal day 10.5. Establishing the vascular localization of ACE2 expression is central to correctly interpret data from modeling COVID-19 in the mouse and may shed light on the cause of vascular COVID-19 complications.Peer reviewe
Recommended from our members
CRLF3 plays a key role in the final stage of platelet genesis and is a potential therapeutic target for thrombocythemia.
Get PDFThe process of platelet production has so far been understood to be a 2-stage process: megakaryocyte maturation from hematopoietic stem cells followed by proplatelet formation, with each phase regulating the peripheral blood platelet count. Proplatelet formation releases into the bloodstream beads-on-a-string preplatelets, which undergo fission into mature platelets. For the first time, we show that preplatelet maturation is a third, tightly regulated, critical process akin to cytokinesis that regulates platelet count. We show that deficiency in cytokine receptor-like factor 3 (CRLF3) in mice leads to an isolated and sustained 25% to 48% reduction in the platelet count without any effect on other blood cell lineages. We show that Crlf3-/- preplatelets have increased microtubule stability, possibly because of increased microtubule glutamylation via the interaction of CRLF3 with key members of the Hippo pathway. Using a mouse model of JAK2 V617F essential thrombocythemia, we show that a lack of CRLF3 leads to long-term lineage-specific normalization of the platelet count. We thereby postulate that targeting CRLF3 has therapeutic potential for treatment of thrombocythemia
A gain-of-function variant in <i>DIAPH1 </i>causes dominant macrothrombocytopenia and hearing loss
Get PDFMacrothrombocytopenia (MTP) is a heterogeneous group of disorders characterized by enlarged and reduced numbers of circulating platelets, sometimes resulting in abnormal bleeding. In most MTP, this phenotype arises because of altered regulation of platelet formation from megakaryocytes (MK). We report the identification of DIAPH1, which encodes the Rho-effector diaphanous-related formin 1 (DIAPH1), as a candidate gene for MTP using exome sequencing, ontological phenotyping and similarity regression. We describe two unrelated pedigrees with MTP and sensorineural hearing loss that segregate with a DIAPH1 p.R1213* variant predicting partial truncation of the DIAPH1 diaphanous autoregulatory domain. The R1213* variant was associated with reduced proplatelet formation from cultured MKs, cell clustering and abnormal cortical filamentous actin. Similarly, in platelets there was increased filamentous actin and stable microtubules, indicating constitutive activation of DIAPH1. Over-expression of DIAPH1 R1213* in cells reproduced the cytoskeletal alterations found in platelets. Our description of a novel disorder of platelet formation and hearing loss extends the repertoire of DIAPH1-related disease and provides new insights into the autoregulation of DIAPH1 activity
Recommended from our members
Functional redundancy between RAP1 isoforms in murine platelet production and function
Get PDFRAP GTPases, important regulators of cellular adhesion, are abundant signaling
molecules in the platelet/megakaryocytic lineage. However, mice lacking the predominant isoform, RAP1B, display a partial platelet integrin activation defect and have a normal platelet count, suggesting the existence of a RAP1-independent pathway to integrin activation in platelets and a negligible role for RAP GTPases in megakaryocyte biology. To determine the importance of individual RAP isoforms on platelet production and on platelet activation at sites of mechanical injury or vascular leakage, we conditionally deleted Rap1a and/or Rap1b in the megakaryocytic lineage (mKO). Interestingly, Rap1a/b-mKO mice displayed a marked macrothrombocytopenia due to impaired pro- platelet formation by megakaryocytes. In platelets, RAP isoforms had both redundant and
isoform-Ëspecific functions. Deletion of RAP1B, but not RAP1A, significantly reduced α- granule secretion and activation of the cytoskeleton regulator RAC1. Both isoforms significantly contributed to thromboxane A2 generation and the inside-out activation of platelet integrins. Combined deficiency of RAP1A and RAP1B markedly impaired platelet aggregation, spreading and clot retraction. Consistently, thrombus formation in physiological flow conditions was abolished in Rap1a/b-mKO, but not Rap1a-mKO or Rap1b-mKO platelets. Rap1a/b-mKO mice were strongly protected from experimental thrombosis and exhibited a severe defect in hemostasis after mechanical injury. Surprisingly, Rap1a/b-mKO platelets were indistinguishable from controls in their ability to prevent blood-lymphatic mixing during development and hemorrhage at sites of inflammation.
In summary, our studies demonstrate an essential role for RAP1 signaling in platelet
integrin activation and a critical role in platelet production. While important for
hemostatic/thrombotic plug formation, platelet RAP1 signaling is dispensable for vascular integrity during development and inflammation
Die Rolle des Zytoskeletts in der Thrombopoese und der Pathogenese von Thrombozytopathien im Menschen und der Maus
No full textPlatelets are continuously produced from megakaryocytes (MK) in the bone marrow by a cytoskeleton-driven process of which the molecular regulation is not fully understood.
As revealed in this thesis, MK/ platelet-specific Profilin1 (Pfn1) deficiency results in micro- thrombocytopenia, a hallmark of the Wiskott-Aldrich syndrome (WAS) in humans, due to accelerated platelet turnover and premature platelet release into the bone marrow. Both Pfn1-deficient mouse platelets and platelets isolated from WAS patients contained abnormally organized and hyper-stable microtubules. These results reveal an unexpected function of Pfn1 as a regulator of microtubule organization and point to a previously unrecognized mechanism underlying the platelet formation defect in WAS patients.
In contrast, Twinfilin2a (Twf2a) was established as a central regulator of platelet reactivity and turnover. Twf2a-deficient mice revealed an age-dependent macrothrombocytopenia that could be explained by a markedly decreased platelet half-life, likely due to the pronounced hyper-reactivity of platelets. The latter was characterized by sustained integrin acti- vation and thrombin generation in vitro that translated into accelerated thrombus formation in vivo. To further elucidate mechanisms of integrin activation, Rap1-GTP-interacting adaptor molecule (RIAM)-null mice were generated. Despite the proposed critical role of RIAM for platelet integrin activation, no alterations in this process could be found and it was concluded that RIAM is dispensable for the activation of ÎČ1 and ÎČ3 integrins, at least in platelets. These findings change the current mechanistic understanding of platelet integrin activation.
Outside-in signaling by integrins and other surface receptors was supposed to regulate MK migration, but also the temporal and spatial formation of proplatelet protrusions. In this the- sis, phospholipase D (PLD) was revealed as critical regulator of actin dynamics and podo- some formation in MKs. Hence, the unaltered platelet counts and production in mice and the absence of a premature platelet release in the bone marrow of mice question the role of podosomes in platelet production and raise the need to reconsider the proposed inhibitory signaling by α2ÎČ1 integrins on proplatelet formation.
Non-muscle myosin IIA (NMMIIA) has been implicated as a downstream effector of the in- hibitory signals transmitted via α2ÎČ1 integrins. Besides Rho-GTPase signaling, also and transient receptor potential melastatin-like 7 (TRPM7) channel α-kinase are known regulators of NMMIIA activity. In this thesis, TRPM7 was identified as major regulator of homeostasis in MKs and platelets. Furthermore, decreased led to deregulated NMMIIA activity and altered cytoskeletal dynamics that impaired thrombopoiesis and resulted in macrothrombocytopenia in humans and mice.Thrombozyten werden kontinuierlich durch einen Zytoskelett-getriebenen Prozess von Megakaryozyten (MK) im Knochenmark gebildet. Die zugrunde liegenden molekularen Me- chanismen sind jedoch weitestgehend unverstanden.
In dieser Thesis konnte gezeigt werden, dass eine MK/ Thrombozyten-spezifische Profilin1 (Pfn1) Defizienz eine Mikrothrombozytopenie verursacht, die das Hauptmerkmal des Wiskott- Aldrich Syndroms (WAS) im Menschen ist. Die reduzierte Thrombozytenzahl konnte auf eine beschleunigte Entfernung der Thrombozyten aus der Zirkulation sowie deren vorzeitige Freisetzung im Knochenmark zurĂŒckgefĂŒhrt werden. Sowohl Thrombozyten von Pfn1- defizienten MĂ€usen, als auch von Patienten mit WAS wiesen abnormal organisierte und hyper-stabile Mikrotubuli auf. Die im Rahmen dieser Thesis gewonnenen Ergebnisse zeigen eine unerwartete Funktion von Pfn1 als Regulator der Mikrotubuliorganisation und weisen auf einen bisher nicht erkannten Mechanismus hin, welcher dem Thrombozytenproduktionsde- fekt in Patienten mit WAS zugrunde liegt.
Im Gegensatz hierzu konnte Twinfilin2a (Twf2a) als zentraler Regulator der Thrombozyten- reaktivitĂ€t und Lebenspanne etabliert werden. MĂ€use mit einer Twf2a Defizienz zeigten eine progressive Makrothrombozytopenie, die durch eine stark reduzierte Lebenspanne der Thrombozyten erklĂ€rt werden konnte. Letzteres war höchstwahrscheinlich durch eine erhöhte Empfindlichkeit von Twf2a-defizienten Thrombozyten gegenĂŒber von aktivierenden Stimuli bedingt. Die HyperreaktivitĂ€t von Twf2a-defizienten Thrombozyten zeigte sich durch eine verlĂ€ngerte Aktivierung der Integrine und erhöhter Thrombingenerierung in vitro sowie be- schleunigter Thrombusbildung in vivo.
Um die Mechanismen der Integrinaktivierung besser zu charakterisieren, wurden Rap1-GTP- interacting adaptor molecule (RIAM)-null MĂ€use generiert. Obwohl RIAM eine zentrale Rolle in der thrombozytĂ€ren Integrinaktivierung zugeschriebenen wurde, konnten keine Defekte in diesem Prozess in RIAM-null Thrombozyten identifiziert werden. Dies fĂŒhrte zu der Schluss- folgerung, dass RIAM fĂŒr die Aktivierung von ÎČ1 und ÎČ3 Integrinen in Thrombozyten nicht benötigt wird. Diese Erkenntnisse verĂ€ndern das gegenwĂ€rtige mechanistische VerstĂ€ndnis der Integrinaktivierung in Thrombozyten.
Die outside-in Signalgebung durch Integrine und andere OberflĂ€chenrezeptoren reguliert die Migration sowie die zeitliche und rĂ€umliche Bildung von proplatelets durch MKs. In dieser Thesis konnte gezeigt werden, dass Phospholipase D (PLD) ein zentraler Regulator der Aktindynamik und Podosomenbildung in MKs ist. Die normale Thrombozytenzahl und -Produktion in MĂ€usen sowie die fehlende vorzeitige Freisetzung von Thrombozytenim Knochenmark von MĂ€usen, stellen die Funktion von Podosomen in der Throm- bozytenproduktion in Frage. Ferner zeigen diese Ergebnisse, dass die Rolle der inhibitori- schen Signalgebung durch α2ÎČ1 Integrine in der proplatelet-Bildung noch einmal ĂŒberdacht werden muss.
Non-muscle myosin IIA (NMMIIA) wird als Effektorprotein im α2ÎČ1 Integrinsignalweg ange- sehen. Neben Signalen, die durch Rho-GTPasen vermittelt werden, regulieren auch und die α-Kinase des transient receptor potential melastatin-like 7 (TRPM7) Kanals die Akti- vitĂ€t von NMMIIA. Im Rahmen dieser Thesis wurde TRPM7 als Hauptregulator der Homöostase in MKs und Thrombozyten identifiziert. DarĂŒber hinaus fĂŒhrten erniedrigte intra- zellulĂ€re Konzentrationen zu einer verĂ€nderten NMMIIA AktivitĂ€t und Zytoskelettdyna- mik. Diese Defekte beeintrĂ€chtigten die Thrombopoese und verursachten eine Makrothrom- bozytopenie im Menschen und der Maus
Homeostatic maintenance of the lymphatic vasculature
No full textThe lymphatic vasculature is emerging as a multifaceted regulator of tissue homeostasis and regeneration. Lymphatic vessels drain fluid, macromolecules, and immune cells from peripheral tissues to lymph nodes (LNs) and the systemic circulation. Their recently uncovered functions extend beyond drainage and include direct modulation of adaptive immunity and paracrine regulation of organ growth. The developmental mechanisms controlling lymphatic vessel growth have been described with increasing precision. It is less clear how the essential functional features of lymphatic vessels are established and maintained. We discuss the mechanisms that maintain lymphatic vessel integrity in adult tissues and control vessel repair and regeneration. This knowledge is crucial for understanding the pathological vessel changes that contribute to disease, and provides an opportunity for therapy development
Inherited platelet diseases with normal platelet count : phenotypes, genotypes and diagnostic strategy
Get PDFInherited platelet disorders resulting from platelet function defects and a normal platelet count cause a moderate or severe bleeding diathesis. Since the description of Glanzmann thrombasthenia resulting from defects of ITGA2B and ITGB3, new inherited platelet disorders have been discovered, facilitated by the use of high throughput sequencing and genomic analyses. Defects of RASGRP2 and FERMT3 responsible for severe bleeding syndromes and integrin activation have illustrated the critical role of signaling molecules. Important are mutations of P2RY12 encoding the major ADP receptor causal for an inherited platelet disorder with inheritance characteristics that depend on the variant identified. Interestingly, variants of GP6 encoding the major subunit of the collagen receptor GPVI/FcR gamma associate only with mild bleeding. The numbers of genes involved in dense granule defects including Hermansky-Pudlak and Chediak Higashi syndromes continue to progress and are updated. The ANO6 gene encoding a Ca2+-activated ion channel required for phospholipid scrambling is responsible for the rare Scott syndrome and decreased procoagulant activity. A novel EPHB2 defect in a familial bleeding syndrome demonstrates a role for this tyrosine kinase receptor independent of the classical model of its interaction with ephrins. Such advances high light the large diversity of variants affecting platelet function but not their production, despite the difficulties in establishing a clear phenotype when few families are affected. They have provided insights into essential pathways of platelet function and have been at the origin of new and improved therapies for ischemic disease. Nevertheless, many patients remain without a diagnosis and requiring new strategies that are now discussed
